POM Investment Strategies LLC Buys 389 Shares of GSK plc (NYSE:GSK)

POM Investment Strategies LLC grew its stake in GSK plc (NYSE:GSK) by 7.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,560 shares of the pharmaceutical company’s stock after acquiring an additional 389 shares during the period. POM Investment Strategies LLC’s holdings in GSK were worth $214,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. JTC Employer Solutions Trustee Ltd grew its position in shares of GSK by 71.3% during the 1st quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock worth $909,063,000 after buying an additional 8,800,822 shares in the last quarter. Hsbc Holdings PLC bought a new position in GSK during the 4th quarter worth about $92,281,000. Armistice Capital LLC increased its position in GSK by 670.5% during the 4th quarter. Armistice Capital LLC now owns 2,196,000 shares of the pharmaceutical company’s stock valued at $81,384,000 after purchasing an additional 1,911,000 shares during the period. Mondrian Investment Partners LTD raised its holdings in shares of GSK by 37.8% in the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock valued at $236,250,000 after purchasing an additional 1,512,442 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in shares of GSK by 10.8% in the 4th quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock worth $558,330,000 after purchasing an additional 1,465,165 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Argus raised shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Berenberg Bank upgraded GSK to a “strong-buy” rating in a report on Thursday, June 20th. Citigroup upgraded GSK to a “strong-buy” rating in a research note on Monday, June 24th. UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Finally, The Goldman Sachs Group began coverage on shares of GSK in a report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price for the company. Three analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, GSK currently has a consensus rating of “Buy” and an average price target of $50.00.

GSK Stock Up 1.6 %

GSK stock traded up $0.68 on Friday, hitting $42.63. 3,780,536 shares of the company’s stock were exchanged, compared to its average volume of 3,539,795. The firm has a 50 day moving average price of $39.82 and a two-hundred day moving average price of $41.51. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.92. The stock has a market cap of $88.35 billion, a P/E ratio of 15.45, a price-to-earnings-growth ratio of 1.32 and a beta of 0.64. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.58 and a current ratio of 0.82.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be paid a dividend of $0.3843 per share. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.61%. GSK’s payout ratio is presently 54.71%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.